期刊文献+

高糖作用的肾小球系膜细胞SnoN/Ski蛋白表达及泛素化降解 被引量:4

Ubiquitin-dependent degradation of SnoN/Ski protein in glomerular mesangial cells induced by high glucose
下载PDF
导出
摘要 目的:观察高糖作用的大鼠肾小球系膜细胞内核转录共抑制因子SnoN/Ski及泛素连接酶Arkadia的表达变化,初步探讨SnoN/Ski泛素化降解在糖尿病肾病中的作用。方法:将体外培养的大鼠肾小球系膜细胞分别设正常对照组、高糖甲组(培养基含20 mmol/L葡萄糖)、高糖乙组(培养基含30 mmol/L葡萄糖)、高糖+MG132组(30 mmol/L葡萄糖培养基中预先加入0.5μmol/L特异性泛素蛋白酶体抑制剂MG132)和甘露醇组。用蛋白免疫印迹技术和免疫荧光染色-激光共聚焦显微镜检测各组细胞SnoN/Ski及Arkadia蛋白的表达。结果:(1)正常系膜细胞中SnoN/Ski蛋白大量表达,Arkadia蛋白表达较弱。(2)高糖作用后SnoN/Ski蛋白表达减弱,Arkadia蛋白表达增强(P<0.05)。(3)与高糖组比较,高糖加入MG132后SnoN/Ski蛋白表达增加,Arkadia蛋白表达减弱(P<0.01)。(4)甘露醇组与正常组比较SnoN/Ski及Arkadia蛋白表达均无明显差异(P>0.05)。结论:(1)高糖可通过泛素蛋白酶体途径降解SnoN/Ski蛋白致其低表达。(2)E3连接酶Arkadia参与了高糖诱导的SnoN/Ski的泛素化降解。 AIM:To observe the protein expression of SnoN/Ski and ubiqutin ligase Arkadia in rat glomerular mesangial cells(GMCs) exposed to the high glucose.METHODS:Cultured rat glomerular mesangial HBZY-1 cells were divided into control group,20 mmol/L glucose group,30 mmol/L glucose group,30 mmol/L glucose + MG132 group (culture medium containing 30 mmol/L glucose and 0.5μmol/L specific proteasome inhibitor MG132),and mannitol group.The expression levels of SnoN,Ski and Arkadia were measured by Western blotting analysis,immunofluorescence and laser scanning confocal microscopy.RESULTS:In control GMCs,the expression of SnoN/Ski was rich and Arkadia was weak.After stimulated with high glucose,the expression of SnoN/Ski was decreased and Arkadia was gradually increased (P〈0.05).Compared with high glucose group,the levels of SnoN/Ski and Arkadia were mostly reverted by adding the proteasome inhibitor MG132 at concentration of 0.5μmol/L(P〈 0.01 ).The expression levels of SnoN/Ski and Arkadia were not significantly changed in mannitol group in comparison with control group(P〉0.05 ).CONCLUSION: High glucose decreases the expression of SnoN/Ski through ubiquitin-dependent degradation of SnoN/Ski.The degradation of SnoN/Ski mediated by Arkadia may play an important role in the pathogenesis of diabetic nephropathy.
出处 《中国病理生理杂志》 CAS CSCD 北大核心 2012年第3期506-511,共6页 Chinese Journal of Pathophysiology
基金 四川省杰出青年基金资助项目(No.2008-26-366) 国家自然科学基金资助项目(No.30670980)
关键词 SnoN/Ski 泛素-蛋白酶体通路 Arkadia 糖尿病肾病 SnoN/Ski Ubiquitin-proteasome pathway Arkadia Diabetic nephropathies
  • 相关文献

参考文献12

  • 1Wynn TA.Cellular and molecular mechanisms of fibrosis [J].J Pathol,2008,214(2):199-210.
  • 2Yang JW,Liu YH.Blockage of tubular epithelial to myofibroblast transition by hepatocyte growth factor prevents renal interstitial fibrosis[J].J Am Soc Nephrol,2002, 13(1):96-107.
  • 3徐玲,杨军,欧阳芳,徐勇,马红艳.高糖对大鼠肾系膜细胞泛素及泛素化蛋白表达的影响[J].中华肾脏病杂志,2009,25(11):853-855. 被引量:2
  • 4Yang JW,Zhang XH,Li YJ,et al.Downregulation of smad transcriptional corepressors SnoN and Ski in the fibrotic kidney:an amplification mechanism for TGF-β1 signaling[J].J Am Soc Nephrol,2003,14(12):3167-3177.
  • 5Fukasawa H,Yamamoto T,Togawa A,et al.Ubiquitin-dependent degradation of SnoN and Ski is increased in renal fibrosis induced by obstructive injury[J].Kidney Int, 2006,69(10):1733-1740.
  • 6Myung J,Kim KB,Crews CM.The ubiquitin-proteasome inhibitors[J].Med Res Rev,2001,21(4):245-273.
  • 7LeckerSH,Goldberg AL,Mitch WE.Protein degradation by the ubiquitin-proteasome pathway in normal and disease states[J].J Am Soc Nephrol,2006,17(7):1807-1819.
  • 8Lu ZM,Hunter T.Degradation of activated protein kinases by ubiquitination[J].Annu Rev Biochem,2009,78: 435-475.
  • 9Koinuma D,Shinozaki M,Komuro A,et al.Arkadia amplifies TGF-beta superfamily signalling through degradation of Smad7[J].EMBO J,2003,22(24):6458-6470.
  • 10Yoshiko N,Konstantinos JM,Kian LL,et al.Arkadia induces degradation of SnoN and c-Ski to enhance transforming growth factor-βsignaling[J].J Biol Chem,2007, 282(28):20492-20501.

二级参考文献6

  • 1马立彬,刘丽蓉,刘晓城,徐钢,曾锐,何晓峰,刘蔚.MG132对TGF-β1诱导的人肾小管上皮细胞Smad泛素化调节因子2和Smad7的影响[J].中华肾脏病杂志,2006,22(12):771-772. 被引量:8
  • 2yon Mikecz A, Chen M, Rockel T, et al. The nuclear ubiquitin-proteasome system: visualization of proteasomes, protein aggregates, and proteolysis in the cell nucleus. Methods Mol Biol, 2008, 463: 191-202.
  • 3Fernandes R, Ramalho J, Pereira P. Oxidative stress upregulates ubiquitin proteasome pathway in retinal endothelial cells. Mol Vis, 2006, 12: 1526-1535.
  • 4Akarsu E, Pirim I, Capoglu I, et al. Relationship between electron- eurographic changes and serum ubiquilin levels in patienls with lype 2 diabetes. Diabetes Care, 2001, 24: 100-103.
  • 5Tan R, Zhang J, Tan X, et al. Downregulation of SnoN expression in obstructive nephropathy is mediated by an enhanced ubiquitin- dependent degradation. J Am Snc Nephrol, 2006, 17: 2781-2791.
  • 6马红艳,徐勇,徐玲,杨军,徐芬.泛素蛋白酶体途径对高糖刺激的肾系膜细胞Smad7表达的影响[J].中国病理生理杂志,2009,25(3):572-576. 被引量:5

共引文献1

同被引文献59

  • 1Jemal A, Bray F, Center MM, et al. Global cancer statis- tics[J]. CA Cancer J Clin, 2011,61(2) :69-90.
  • 2Azzoli CG, Temin S, Aliff T, et al. 2011 Focused Update of 2009 American Society of ClinieM Oncology Clinical Practice Guideline Update on Chemotherapy for Stage Ⅳ Non-Small-Cell Lung Cancer[J]. J Clin Oncol, 2011, 29 ( 28 ) : 3825-3831.
  • 3Goffin J, Lacchetti C, Ellis PM, et al. First-line systemic chemotherapy in the treatment of advanced non-small-cell lung cancer: a systematic review [ J]. J Thorac Oncol, 2010, 5(2) :260-274.
  • 4Soon YY, Stockier MR, Askie LM, et al. Duration of chemotherapy for advanced non-small cell lung cancer: a systematic review and meta-analysis of randomized trials [J]. J Clin Oncol, 2009, 27(20):3277-3283.
  • 5Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a ran- domised, double-blind, phase 3 study [ J ]. Lancet, 2009, 374(9699) : 1432-1440.
  • 6Cappuzzo F, Ciuleanu T, Stelmakh L, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a muhicentre, randomised, placebo-controlled phase 3 study[J]. Lancet Oncol, 2010, 11 (6) :521-529.
  • 7Miller VA, O'Connor P, Soh C, et al. A randomized, double-blind, placebo-controlled, phase IIIb trial (AT- LAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or me- tastatic non-small cell lung cancer (NSCLC) [ J ]. J Clin Oncol, 2009, 27(18S):LBA8002.
  • 8Belani CP, Waterhouse DM, Ghazal H, et al. Phase Ⅲ study of maintenance gemcitabine (G) and best supportive care (BSC) versus BSC, following standard combination therapy with gemcitabine-carboplatin (G-Cb) for patients with advanced non-small cell lung cancer (NSCLC) [ J ]. J Clin Oncol, 2010, 28(15 Suppl) : 7506.
  • 9Belani CP, Brodowicz T, Ciuleanu T, et al. Maintenance pemetrexed (Pem) plus best supportive care (BSC) ver- sus placebo (Plac) plus BSC: a randomized phase Ⅲ study in advancednon-small cell lung cancer (NSCLC) [J]. J Clin Oncol, 2009, 27(18S):CRAB000.
  • 10Cappuzzo F, Ciuleanu T, Stelmakh L, et al. SATURN: A double-blind, randomized, phase Ⅲ study of maintenance erlotinib versus placebo following nonprogression with first- line platinum-based chemotherapy in patients with ad- vanced NSCLC [ J ]. J Clin Oncol, 2009, 27 (15S) : 8001.

引证文献4

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部